Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.67 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.67 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PLAU | P00749 | 4/20 | 0.54 |
| ▸ | F10 | P00742 | 3/20 | 0.54 |
| ▸ | PLAT | P00750 | 3/20 | 0.54 |
| ▸ | KLK1 | P06870 | 2/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.54 |
| ▸ | PLG | P00747 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21555763 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL13855058 | 0.82 | F2 (0.54) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL9609808 | 0.82 | SMN1; SMN2 (0.82) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL7903320 | 0.81 | F2 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11658715 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL4553738 | 0.80 | F2 (0.77) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL29246859 | 0.79 | F2 (0.69) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL2094519 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL3001175 | 0.79 | SMN1; SMN2 (0.64) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL8886838 | 0.79 | MEN1 (0.69) | SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2794597-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093484-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | F2 5/4885PRSS1 254/4885PRSS2 698/4885 |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | F2 2/4885PRSS1 74/4885PRSS2 131/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | F2 5/4885PRSS1 254/4885PRSS2 698/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | F2 6/4885PRSS1 72/4885PRSS2 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.